News
-
-
-
-
-
-
-
PRESS RELEASE
Original-Research: init innovation in traffic systems SE (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Research update on init innovation in traffic systems SE by Quirin Privatbank Kapitalmarktgeschäft, confirming full year guidance. EUR 75.7m orders in Q1-25 with revenues of EUR 70.4m. EBIT at EUR 2.0m -
PRESS RELEASE
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for interchangeability of FYB202/Otulfi (ustekinumab-aauz) with Stelara, enhancing patient access to treatment options for inflammatory diseases in the US -
PRESS RELEASE
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
PL BioScience and DewCell sign LOI to jointly develop artificial human platelets for scalable, animal-free cell culture media. The collaboration aims to meet demand driven by regulatory trends in cell- and gene therapy development -
PRESS RELEASE
Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions
Interactive Strength Inc. (Nasdaq:TRNR) raises its 2025 pro forma revenue guidance to over $75M. Read about the update and acquisition details on the Company's investor website and SEC filings